TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34107512

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (0.1 g·kg‐1·d‐1) during resistance training (3 d·wk‐1 for 1 yr)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo during resistance training
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 32302717

Group type: EXPERIMENTAL
Intervention: Extended hours dialysis (≥ 24 hours/week)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard hours dialysis (12‐18 hours/week)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Reduction in ultrafiltration rate
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Reduction in systolic blood pressure
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Reduction in interdialytic weight gain
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Change in urea clearance, phosphate, or total hours per week
Number of subjects: 200
Study: 35220948

Group type: EXPERIMENTAL
Intervention: Single suction device for processing cumulative blood including amniotic fluid (Group 1)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Two suction devices to separate amniotic fluid from cumulative blood (Group 2)
Number of subjects: 34
Study: 33885394

Group type: EXPERIMENTAL
Intervention: Clinical skills simulation (CSS) using standardized patient
Number of subjects: 50

Group type: COMPARATOR
Intervention: Traditional methods of teaching behavior management
Number of subjects: 50
Study: 34369941

Group type: EXPERIMENTAL
Intervention: IANB plus buccal infiltration (1.8 mL IANB + 1.8 mL buccal infiltration)
Number of subjects: 60

Group type: COMPARATOR
Intervention: IANB (3.6 mL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: IANB plus lingual infiltration (1.8 mL IANB + 1.8 mL lingual infiltration)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: IANB, IANB plus buccal infiltration, IANB plus lingual infiltration
Number of subjects: 60
Study: 33126910

Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg once daily for 10 days)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Aspirin (75 mg once daily for 10 days)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Aspirin + Atorvastatin with conventional therapy
Number of subjects: 800

Group type: COMPARATOR
Intervention: Control (usual care for management of COVID-19)
Number of subjects: 800
Study: 35356608

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation combined with radioactive seed implantation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Radiofrequency ablation only
Number of subjects: 30
Study: 32918160

Group type: EXPERIMENTAL
Intervention: SLH formulations (SLH-A and SLH-B)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Commercial formulation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: SLH formulations
Number of subjects: 12
Study: 34382353

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 19
Study: 32739331

Group type: EXPERIMENTAL
Intervention: Nutritional information present
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nutritional information absent
Number of subjects: 0
Study: 35883085

Group type: EXPERIMENTAL
Intervention: External focus group
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Internal focus group
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study: 32931645

Group type: EXPERIMENTAL
Intervention: ExeRTiOn online resource
Number of subjects: 17
Study: 32741642

Group type: EXPERIMENTAL
Intervention: Pregabalin 75 mg preoperatively
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 35444232

Group type: EXPERIMENTAL
Intervention: BenMel (200 mg/m2 bendamustine + 100 mg/m2 melphalan)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Mel (200 mg/m2 melphalan)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: BenMel
Number of subjects: 120

Group type: COMPARATOR
Intervention: Mel
Number of subjects: 120
Study: 32743758

Group type: EXPERIMENTAL
Intervention: Active tDCS with standard bifrontal montage (anode over left DLPFC, cathode over right DLPFC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 20
Study: 36115625

Group type: EXPERIMENTAL
Intervention: USCAP
Number of subjects: 130
Study: 33574503

Group type: EXPERIMENTAL
Intervention: Rhizobium strains NSFBR‐15 and NSFBR‐12
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-inoculated plants without N fertilizer (‐N control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-inoculated plants with N fertilizer (+N control)
Number of subjects: 0
Study: 32605697

Group type: EXPERIMENTAL
Intervention: Injected allergen-specific immunotherapy (AIT) for grass pollen allergy
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 35511051

Group type: EXPERIMENTAL
Intervention: Nissen fundoplication
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Toupet fundoplication
Number of subjects: 70
Study: 32700389

Group type: EXPERIMENTAL
Intervention: Physician incentives of $50 per patient per drug class
Number of subjects: 8935

Group type: COMPARATOR
Intervention: Control group (no physician incentives)
Number of subjects: 8935
Study: 33533134

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Intense pulsed light (IPL)
Number of subjects: 28
Study: 32222849

Group type: EXPERIMENTAL
Intervention: Peer‐led healthy lifestyle intervention
Number of subjects: 314
Study: 34342706

Group type: EXPERIMENTAL
Intervention: Robot-assisted surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laparoscopic surgical resection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open surgical approach
Number of subjects: 0
Study: 36317831

Group type: EXPERIMENTAL
Intervention: Post-show video discussion about the character's motives and actions
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Pre-show warning about an untrustworthy character
Number of subjects: 334

Group type: COMPARATOR
Intervention: Control clip (no narrative correction)
Number of subjects: 334
Study: 34008397

Group type: EXPERIMENTAL
Intervention: Bedtime levothyroxine administration (group A)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Early morning levothyroxine administration (group B)
Number of subjects: 84
Study: 32641379

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 6522

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6522
Study: 35272337

Group type: EXPERIMENTAL
Intervention: Educational video
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard handout
Number of subjects: 38
Study: 32006473

Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin plus GVHD prophylaxis
Number of subjects: 99

Group type: COMPARATOR
Intervention: Standard GVHD prophylaxis
Number of subjects: 99
Study: 36347740

Group type: EXPERIMENTAL
Intervention: mAFA intervention
Number of subjects: 714
Study: 32790913

Group type: EXPERIMENTAL
Intervention: Amoxicillin + Clavulanic acid
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Amoxicillin + Clavulanic acid + Probiotics
Number of subjects: 159

Group type: COMPARATOR
Intervention: No antibiotics or probiotics (Control)
Number of subjects: 159
Study: 32482626

Group type: EXPERIMENTAL
Intervention: Outcome Prioritisation Tool (OPT)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 114
Study: 36243020

Group type: EXPERIMENTAL
Intervention: Chronic convection-enhanced delivery of topotecan (146 μM, 200 μL/h for 48 h, followed by a 5-7 day washout period, with four total infusions)
Number of subjects: 5
Study: 33686901

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Family income level
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Gender
Number of subjects: 128
Study: 35131486

Group type: EXPERIMENTAL
Intervention: Reduced intensity conditioning with bortezomib (Bz) prior to alloSCT
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Post-transplant maintenance with bortezomib (Bz) and lenalidomide (Len)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Event free survival (EFS) and overall survival (OS)
Number of subjects: 24
Study: 34507338

Group type: EXPERIMENTAL
Intervention: Symptom Navi Program (SNP)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 134
Study: 35234931

Group type: EXPERIMENTAL
Intervention: IPS integrated with TAU
Number of subjects: 58

Group type: COMPARATOR
Intervention: TAU alone
Number of subjects: 58
Study: 32885780

Group type: EXPERIMENTAL
Intervention: Invitation letter including a FIT (n = 5850)
Number of subjects: 17532

Group type: EXPERIMENTAL
Intervention: Invitation letter including an option to request a FIT (n = 5844)
Number of subjects: 17532

Group type: EXPERIMENTAL
Intervention: Reminder letters sent to group A
Number of subjects: 17532

Group type: EXPERIMENTAL
Intervention: Reminder letters sent to group B
Number of subjects: 17532

Group type: COMPARATOR
Intervention: Control group (invitation letter only, n = 5838)
Number of subjects: 17532

Group type: EXPERIMENTAL
Intervention: FIT positivity rate
Number of subjects: 17532

Group type: EXPERIMENTAL
Intervention: Subsequent colonoscopy for FIT‐positive participants
Number of subjects: 17532
Study: 34311059

Group type: EXPERIMENTAL
Intervention: Virtual Reality Training (VRT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Conventional Balance Training (CBT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control
Number of subjects: 36
Study: 34927405

Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Concentrated growth factors (CGF)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Autologous fibrin glue (AFG)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19
Study: 32969717

Group type: EXPERIMENTAL
Intervention: Multiomics data analysis approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylation probes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel loci (C5orf38, SF3A3, DHX36, MRPL33)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SELE protein level
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylation site cg05126514 within the BSN gene
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transcriptional regulatory genes (SF3A3, ILF3, N4BP2L2)
Number of subjects: 0
Study: 34965188

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention combined with standard care (N = 64)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Standard care alone (N = 34)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention and/or pharmacological interventions
Number of subjects: 98
Study: 33678124

Group type: EXPERIMENTAL
Intervention: Second-look resection (SLR) performed in 642 (26%) individuals
Number of subjects: 2456

Group type: EXPERIMENTAL
Intervention: Second-look resection (SLR)
Number of subjects: 2456
Study: 32119096

Group type: EXPERIMENTAL
Intervention: Pregnenolone
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 34284374

Group type: EXPERIMENTAL
Intervention: Glass ionomer sealant (GIS) - 1 single placement
Number of subjects: 323
Study: 35466448

Group type: EXPERIMENTAL
Intervention: Romosozumab 210 mg sc monthly
Number of subjects: 11224

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11224

Group type: COMPARATOR
Intervention: Alendronate 70 mg po weekly
Number of subjects: 11224

Group type: EXPERIMENTAL
Intervention: Romosozumab
Number of subjects: 11224
Study: 33485453

Group type: EXPERIMENTAL
Intervention: Adavosertib plus gemcitabine
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo plus gemcitabine
Number of subjects: 124
Study: 34736818

Group type: EXPERIMENTAL
Intervention: Kinesio taping
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham taping
Number of subjects: 50
Study: 33838307

Group type: EXPERIMENTAL
Intervention: Integrated care model of long-acting injectable buprenorphine (ID/LAB)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 200
Study: 32719239

Group type: EXPERIMENTAL
Intervention: Minimal endoscopic sphincterotomy followed by papillary balloon dilation (ESBD)
Number of subjects: 435

Group type: COMPARATOR
Intervention: Endoscopic sphincterotomy (EST)
Number of subjects: 435
Study: 34431612

Group type: EXPERIMENTAL
Intervention: Scalp acupuncture (ISSA) at parietal midline [MS5], left anterior parietotemporal oblique line [MS6], left posterior parietotemporal oblique line [MS7] for one course of treatment.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional Western medicine (control group).
Number of subjects: 30
Study: 34290695

Group type: EXPERIMENTAL
Intervention: HIV-positive participants on ART
Number of subjects: 289

Group type: COMPARATOR
Intervention: HIV-negative participants
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: PDL1 immune marker
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Inflammation patterns
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Nine immune markers identified by ANCOVA
Number of subjects: 289
Study: 33126336

Group type: EXPERIMENTAL
Intervention: Transforaminal lumbar interbody fusion (TLIF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Posterior lumbar interbody fusion (PLIF)
Number of subjects: 0
Study: 35180726

Group type: EXPERIMENTAL
Intervention: Cast-saw alarm
Number of subjects: 31
Study: 33158633

Group type: EXPERIMENTAL
Intervention: Traditional corticotomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Flapless corticotomy
Number of subjects: 40
Study: 34311441

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIIE) training for 4 weeks, 3 times per week
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control condition with no intervention for 4 weeks
Number of subjects: 19
Study: 34218211

Group type: EXPERIMENTAL
Intervention: Adjunctive brivaracetam (BRV) at a median modal dose of 150 mg/day for a median treatment duration of 2.5 years.
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Adjunctive brivaracetam (BRV) treatment for ≥ 1 year.
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Adjunctive brivaracetam (BRV) treatment after 1 and 2 years.
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Adjunctive brivaracetam (BRV) treatment.
Number of subjects: 284
Study: 36211683

Group type: EXPERIMENTAL
Intervention: Food advertisements
Number of subjects: 200
Study: 35184471

Group type: EXPERIMENTAL
Intervention: Nomogram for predicting poor ovarian response (POR) based on factors such as age, infertility type, body mass index, anti-Müllerian hormone, basal follicle stimulating hormone, basal estrogen, antral follicle number, previous times of POR, history of ovarian surgery, ovulation stimulation protocol, average amount of gonadotropin.
Number of subjects: 13266
Study: 33231679

Group type: EXPERIMENTAL
Intervention: Healthy Me, Healthy We intervention (8-month social marketing intervention)
Number of subjects: 853

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 853
Study: 32912298

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 140

Group type: COMPARATOR
Intervention: Nontreatment
Number of subjects: 140
Study: 36038128

Group type: EXPERIMENTAL
Intervention: AI-assisted colonoscopy
Number of subjects: 5796

Group type: COMPARATOR
Intervention: Non-AI colonoscopy
Number of subjects: 5796
Study: 34653608

Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D3 (25(OH)D3)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 32761987

Group type: EXPERIMENTAL
Intervention: Workbook training (Phase 1 and Phase 2)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Workbook training (Phase 1)
Number of subjects: 341

Group type: COMPARATOR
Intervention: Control group (Phase 1 and Phase 2)
Number of subjects: 341
Study: 35498888

Group type: EXPERIMENTAL
Intervention: Corticosteroids combined with renin‐angiotensin system blockers (RASBs)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Dapagliflozin combined with RASBs
Number of subjects: 426

Group type: COMPARATOR
Intervention: RASBs alone
Number of subjects: 426
Study: 33590955

Group type: EXPERIMENTAL
Intervention: 2400 mg Aged Garlic Extract (AGE) daily for 1 year
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 33279636

Group type: EXPERIMENTAL
Intervention: Imagined walking along a 5‐m walkway of three different path widths (15, 25, and 50 cm)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Imagined walking along the aforementioned paths while PFC activity was measured using functional near‐infrared spectroscopy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison with young adults from a previous study
Number of subjects: 20
Study: 34990291

Group type: EXPERIMENTAL
Intervention: Two cycles of concurrent 100 mg/m2 DDP
Number of subjects: 332

Group type: COMPARATOR
Intervention: Three cycles of concurrent DDP
Number of subjects: 332
Study: 33797427

Group type: EXPERIMENTAL
Intervention: Depo‐Medrol (40 mg/1 cc)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control (saline 1 cc)
Number of subjects: 73
Study: 32571395

Group type: EXPERIMENTAL
Intervention: Miao crossbow needle therapy (CN)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Acupuncture (AT)
Number of subjects: 301
Study: 35221215

Group type: EXPERIMENTAL
Intervention: Integrated Care Pathway (ICP)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Treatment-As-Usual (TAU)
Number of subjects: 145
Study: 34365776

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 264
Study: 32780643

Group type: EXPERIMENTAL
Intervention: ramucirumab/erlotinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo/erlotinib
Number of subjects: 0
Study: 36152018

Group type: EXPERIMENTAL
Intervention: Oral function intervention (one-on-one lesson on oral exercise and preventive oral care)
Number of subjects: 114
Study: 33710023

Group type: EXPERIMENTAL
Intervention: emtricitabine/tenofovir disoproxil fumarate preexposure prophylaxis (FTC/TDF PrEP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 32404725

Group type: EXPERIMENTAL
Intervention: Continuous Care Model (CCM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 60
Study: 35570712

Group type: EXPERIMENTAL
Intervention: PM-allergoids 3000 mTU SC
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: PM-allergoids 5000 mTU SC
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: PM-allergoids 3000 mTU SL
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: PM-allergoids 5000 mTU SL
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study: 33025730

Group type: EXPERIMENTAL
Intervention: Pomalidomide 2.6 mg/m2 (MTD) given orally once daily for 21 consecutive days of a 28-day cycle
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Pomalidomide 3.4 mg/m2 (dose level 3)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Pomalidomide
Number of subjects: 29
Study: 33175164

Group type: EXPERIMENTAL
Intervention: Low-temperature plasma radiofrequency ablation (LTP-RFA)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Radiofrequency thermocoagulation (RFT)
Number of subjects: 204
Study: 32693653

Group type: EXPERIMENTAL
Intervention: Topical anaesthetic cream (5% lidocaine‐prilocaine cream)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 100
Study: 33612377

Group type: EXPERIMENTAL
Intervention: Customized insole
Number of subjects: 23

Group type: COMPARATOR
Intervention: Toe separator
Number of subjects: 23
Study: 33459175

Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 33753956

Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 32984918

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metabolic surgery (general)
Number of subjects: 0
Study: 32009473

Group type: EXPERIMENTAL
Intervention: Cryo-immuno-therapy (combination of cryotherapy with intralesional Candida antigen)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intralesional Candida antigen monotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cryotherapy alone
Number of subjects: 60
Study: 35666133

Group type: EXPERIMENTAL
Intervention: MITP group (n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (n=30)
Number of subjects: 60
Study: 33177808

Group type: EXPERIMENTAL
Intervention: Dezocine 5mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Sufentanil 5μg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Combination of dezocine and sufentanil (1:3, 1:1, 3:1)
Number of subjects: 150
Study: 35125219

Group type: EXPERIMENTAL
Intervention: MAS-1 adjuvanted IIV (1, 3, 5, or 9 µg per HA)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard dose IIV (Fluzone SD, 15 µg per HA)
Number of subjects: 72
Study: 34473350

Group type: EXPERIMENTAL
Intervention: Remote ischaemic conditioning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no remote ischaemic conditioning)
Number of subjects: 0
Study: 33762179

Group type: EXPERIMENTAL
Intervention: Comprehensive lifestyle-medical treatment to targets and PET guided interventions
Number of subjects: 1028

Group type: COMPARATOR
Intervention: Standard of care (Standard group)
Number of subjects: 1028
Study: 32241789

Group type: EXPERIMENTAL
Intervention: True acupuncture treatment (10 sessions, five sessions per week for 2 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham acupuncture treatment (10 sessions, five sessions per week for 2 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: True acupuncture treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham acupuncture treatment
Number of subjects: 30
Study: 35982492

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) game during dressing changes
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard distraction techniques available in the home
Number of subjects: 35